



NDA 008809/S-065

**SUPPLEMENT APPROVAL**

Hospira, Inc.  
Attention: Kathleen G. Enger  
Manager, Global Regulatory Affairs  
275 N. Field Drive  
Lake Forest, IL 60045

Dear Ms. Enger:

Please refer to your Supplemental New Drug Application (sNDA) dated December 14, 2011, received December 15, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for M.V.I.-12 (Multi-vitamin Infusion without Vitamin K) Pharmacy Bulk Package (PBP).

We acknowledge receipt of your amendments dated September 22, 2010, and December 15, 2011. We also acknowledge receipt of your email dated June 11, 2012, that includes the agreed-upon labeling.

The December 15, 2011, submission constituted a complete response to our December 21, 2010, action letter.

This prior approval labeling supplement new drug application provides for conversion to Physician Labeling Rule (PLR) format.

We have completed our review of this supplemental application as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, and patient package insert), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of labeling Technical Qs and As at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Abolade (Bola) Adeolu, Regulatory Project Manager, at (301) 796-4264.

Sincerely,

*{See appended electronic signature page}*

Mary Parks, M.D.  
Director  
Division of Metabolism and Endocrinology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Enclosure:  
Package Insert

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY H PARKS  
06/14/2012